

# Middle East & Africa Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)

<https://marketpublishers.com/r/M440CF5165EDEN.html>

Date: January 2026

Pages: 218

Price: US\$ 3,450.00 (Single User License)

ID: M440CF5165EDEN

## Abstracts

The Middle East & Africa Anti-Obesity Drugs Market is projected to grow significantly, reaching approximately US\$ 1,064.3 million by 2031, up from US\$ 270.8 million in 2024, with an estimated compound annual growth rate (CAGR) of 22.3% from 2025 to 2031.

## Executive Summary and Market Analysis

The anti-obesity drugs market in the Middle East & Africa is divided into key regions including the UAE, Saudi Arabia, South Africa, and the broader Middle East & Africa. Factors such as increased suburbanization and lifestyle changes have led to a rise in the consumption of high-calorie processed foods and a decrease in physical activity, resulting in higher obesity rates. Additionally, there is a growing awareness of the health risks associated with obesity, such as diabetes, cardiovascular diseases, and certain cancers, which has spurred demand for medical treatments. Governments and health organizations are launching public health initiatives to combat obesity, further driving market growth. Enhanced access to healthcare, rising disposable incomes, and increased investment in healthcare infrastructure are also contributing to this expansion. Moreover, the presence of pharmaceutical companies offering innovative anti-obesity treatments, particularly GLP-1 receptor agonists, is on the rise. As cultural attitudes evolve and medical tourism becomes more prevalent, especially in countries like the UAE and South Africa, the anti-obesity drug market is expected to continue its upward trajectory.

## Strategic Insights

## Market Segmentation Analysis

**By Type:** The market is categorized into Prescription Drugs and OTC Drugs, with Prescription Drugs holding the largest market share in 2024.

**By Mechanism of Action:** Segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others, with Centrally Acting Drugs leading in market share in 2024.

**By Drug Class:** Includes GLP-1 Agonists, Lipase Inhibitors, MC4R Agonists, and Others, where GLP-1 Agonists dominated in 2024.

**By GLP-1 Agonist:** Further divided into Semaglutide, Liraglutide, and Tirzepatide (Zepbound), with Semaglutide being the most prominent in 2024.

**By Application:** Categories include Appetite Suppression, Inhibition of Fat Absorption, Metabolic Enhancement, and Combination, with Appetite Suppression leading the market.

**By Route of Administration:** The market is segmented into Oral and Parenteral, with Oral being the most common route in 2024.

**By Distribution Channel:** Includes Hospital Pharmacies, Online Channels, and Retail Pharmacies, with Hospital Pharmacies holding the largest share.

## **Market Outlook**

Obesity is influenced by genetic, environmental, and lifestyle factors. Recent advancements indicate that individuals respond differently to anti-obesity medications based on their genetic profiles, metabolic rates, gut microbiota, and existing health conditions. This variability means that a medication effective for one patient may not work for another. Precision medicine is emerging in obesity treatment, utilizing pharmacogenomic testing and detailed patient profiling to identify the most effective drug or combination of drugs for each individual. Companies are developing diagnostic tools to analyze genetic markers related to obesity and drug metabolism, aiding clinicians in predicting patient responses to various treatments. The expanding pipeline of anti-obesity drugs targeting different mechanisms allows for tailored therapies that align with individual patient needs. For instance, if a patient does not respond well to a GLP-1 agonist, a physician may consider switching to or combining it with another agent targeting a different pathway.

Pharmacogenomic companies like Acosta and Phenomix are providing tests that support personalized obesity treatment, a trend expected to accelerate as more data and drugs become available. This shift towards individualized treatment regimens is anticipated to enhance the effectiveness, cost-efficiency, and acceptance of anti-obesity pharmacotherapy among patients and healthcare providers. In March 2025, VIVUS LLC launched QSYMIA® (phentermine and topiramate extended-release capsules) in the UAE, marking a significant step in addressing the region's rising obesity rates, projected to affect over 7.5 million people by 2035.

## Country Insights

The market is further segmented by country, with Saudi Arabia holding the largest share in 2024. The prevalence of overweight and obesity in Saudi Arabia has nearly doubled over the past fifty years, with over half the population classified as overweight and more than 20% as obese. The economic burden of obesity management in the country is estimated at US\$ 6.4 billion, underscoring the urgent need for effective interventions. The Saudi government has implemented various policies under its Vision 2030 plan to promote a healthier population.

In April 2025, Novo Nordisk signed a Memorandum of Understanding with Lifera to localize the manufacturing of semaglutide-based GLP-1 treatments in Saudi Arabia, enhancing the country's healthcare infrastructure. This agreement aims to launch Wegovy in Saudi Arabia, making it accessible to patients in both public and private sectors, reflecting the country's commitment to tackling obesity.

## Company Profiles

Key players in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence.

## Contents

### **1. INTRODUCTION**

- 1.1 Report Guidance
- 1.2 Market Segmentation

### **2. EXECUTIVE SUMMARY**

- 2.1 Key Insights
- 2.2 Market Attractiveness

### **3. RESEARCH METHODOLOGY**

- 3.1 Secondary Research
- 3.2 Primary Research
  - 3.2.1 Hypothesis formulation:
  - 3.2.2 Macroeconomic factor analysis:
  - 3.2.3 Developing base number:
  - 3.2.4 Data Triangulation:
  - 3.2.5 Country-level data:

### **4. ANTI-OBESITY DRUGS MARKET LANDSCAPE**

- 4.1 Market Overview
- 4.2 PEST Analysis

### **5. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS**

- 5.1 Market Drivers
- 5.2 Market Restraints
- 5.3 Market Opportunities
- 5.4 Future Trends
- 5.5 Impact of Drivers and Restraints:

### **6. ANTI-OBESITY DRUGS MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS**

6.1 Middle East & Africa Anti-Obesity Drugs Market Revenue (US\$ Million), 2024 - 2031

6.2 Middle East & Africa Anti-Obesity Drugs Market Forecast and Analysis

## **7. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE**

7.1 Prescription Drugs

7.1.1 Overview

7.1.2 Prescription Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

7.2 OTC Drugs

7.2.1 Overview

7.2.2 OTC Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

## **8. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION**

8.1 Centrally Acting Drugs

8.1.1 Overview

8.1.2 Centrally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

8.2 Peripherally Acting Drugs

8.2.1 Overview

8.2.2 Peripherally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

8.3 Others

8.3.1 Overview

8.3.2 Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

## **9. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS**

9.1 GLP-1 Agonist

9.1.1 Overview

9.1.2 GLP-1 Agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

9.2 Lipase Inhibitors

### 9.2.1 Overview

9.2.2 Lipase Inhibitors: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

## 9.3 MC4R agonist

### 9.3.1 Overview

9.3.2 MC4R agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

## 9.4 Others

### 9.4.1 Overview

9.4.2 Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

## **10. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST**

### 10.1 Semaglutide

#### 10.1.1 Overview

10.1.2 Semaglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

### 10.2 Liraglutide

#### 10.2.1 Overview

10.2.2 Liraglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

### 10.3 Tirzepatide (Zepbound)

#### 10.3.1 Overview

10.3.2 Tirzepatide (Zepbound): Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

## **11. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION**

### 11.1 Appetite Suppression

#### 11.1.1 Overview

11.1.2 Appetite Suppression: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

### 11.2 Inhibition of Fat Absorption or Digestive Enzymes

#### 11.2.1 Overview

11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

### 11.3 Metabolic Enhancement

#### 11.3.1 Overview

11.3.2 Metabolic Enhancement: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

### 11.4 Combination

#### 11.4.1 Overview

11.4.2 Combination: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

## **12. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION**

### 12.1 Oral

#### 12.1.1 Overview

12.1.2 Oral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

### 12.2 Parenteral

#### 12.2.1 Overview

12.2.2 Parenteral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

## **13. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL**

### 13.1 Hospital Pharmacies

#### 13.1.1 Overview

13.1.2 Hospital Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

### 13.2 Online Channel

#### 13.2.1 Overview

13.2.2 Online Channel: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

### 13.3 Retail Pharmacies

#### 13.3.1 Overview

13.3.2 Retail Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

## **14. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS**

## 14.1 Middle East & Africa

### 14.1.1 Middle East & Africa Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country

#### 14.1.1.1 Middle East & Africa Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country

#### 14.1.2.2 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

##### 14.1.2.2.1 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Type

##### 14.1.2.2.2 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action

##### 14.1.2.2.3 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class

##### 14.1.2.2.4 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist

##### 14.1.2.2.5 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Application

##### 14.1.2.2.6 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration

##### 14.1.2.2.7 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel

#### 14.2.3.3 South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

##### 14.2.3.3.1 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Type

##### 14.2.3.3.2 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action

##### 14.2.3.3.3 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class

##### 14.2.3.3.4 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist

##### 14.2.3.3.5 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Application

##### 14.2.3.3.6 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration

##### 14.2.3.3.7 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel

#### 14.3.4.4 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market -

## Revenue and Forecast, 2021 - 2031 (US\$ Million)

14.3.4.4.1 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Type

14.3.4.4.2 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.3.4.4.3 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class

14.3.4.4.4 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist

14.3.4.4.5 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Application

14.3.4.4.6 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration

14.3.4.4.7 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel

14.4.5.5 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

14.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Type

14.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class

14.4.5.5.4 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist

14.4.5.5.5 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Application

14.4.5.5.6 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration

14.4.5.5.7 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel

## 15 COMPETITIVE LANDSCAPE

15.1 Heat Map Analysis by Key Players

15.2 Company Positioning & Concentration

## 16 INDUSTRY LANDSCAPE

- 16.1 Overview
- 16.2 New Product Development
- 16.3 Merger and Acquisition
- 16.4 Other Strategic Developments

## **17 COMPANY PROFILES**

- 17.1 GSK Plc
  - 17.1.1 Key Facts
  - 17.1.2 Business Description
  - 17.1.3 Products and Services
  - 17.1.4 Financial Overview
  - 17.1.5 SWOT Analysis
  - 17.1.6 Key Developments
- 17.2 F. Hoffmann-La Roche Ltd
  - 17.2.1 Key Facts
  - 17.2.2 Business Description
  - 17.2.3 Products and Services
  - 17.2.4 Financial Overview
  - 17.2.5 SWOT Analysis
  - 17.2.6 Key Developments
- 17.3 Teva Pharmaceutical Industries Ltd
  - 17.3.1 Key Facts
  - 17.3.2 Business Description
  - 17.3.3 Products and Services
  - 17.3.4 Financial Overview
  - 17.3.5 SWOT Analysis
  - 17.3.6 Key Developments
- 17.4 Novo Nordisk AS
  - 17.4.1 Key Facts
  - 17.4.2 Business Description
  - 17.4.3 Products and Services
  - 17.4.4 Financial Overview
  - 17.4.5 SWOT Analysis
  - 17.4.6 Key Developments
- 17.5 Eli Lilly and Co
  - 17.5.1 Key Facts
  - 17.5.2 Business Description
  - 17.5.3 Products and Services

- 17.5.4 Financial Overview
- 17.5.5 SWOT Analysis
- 17.5.6 Key Developments
- 17.6 Sun Pharmaceutical Industries Ltd
  - 17.6.1 Key Facts
  - 17.6.2 Business Description
  - 17.6.3 Products and Services
  - 17.6.4 Financial Overview
  - 17.6.5 SWOT Analysis
  - 17.6.6 Key Developments
- 17.7 VIVUS LLC
  - 17.7.1 Key Facts
  - 17.7.2 Business Description
  - 17.7.3 Products and Services
  - 17.7.4 Financial Overview
  - 17.7.5 SWOT Analysis
  - 17.7.6 Key Developments
- 17.8 Currax Pharmaceuticals LLC.
  - 17.8.1 Key Facts
  - 17.8.2 Business Description
  - 17.8.3 Products and Services
  - 17.8.4 Financial Overview
  - 17.8.5 SWOT Analysis
  - 17.8.6 Key Developments
- 17.9 AdvaCare Pharma USA LLC
  - 17.9.1 Key Facts
  - 17.9.2 Business Description
  - 17.9.3 Products and Services
  - 17.9.4 Financial Overview
  - 17.9.5 SWOT Analysis
  - 17.9.6 Key Developments
- 17.10 Rhythm Pharmaceuticals Inc
  - 17.10.1 Key Facts
  - 17.10.2 Business Description
  - 17.10.3 Products and Services
  - 17.10.4 Financial Overview
  - 17.10.5 SWOT Analysis
  - 17.10.6 Key Developments

## **18. APPENDIX**

### 18.1 About The Insight Partners

## List Of Tables

### LIST OF TABLES

Table 1. Middle East & Africa Anti-Obesity Drugs Market Segmentation

Table 2. List of Vendors

Table 3. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Table 4. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type

Table 5. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action

Table 6. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class

Table 7. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist

Table 8. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 9. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration

Table 10. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel

Table 11. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Country

Table 12. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type

Table 13. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action

Table 14. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class

Table 15. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist

Table 16. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 17. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration

Table 18. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel

Table 19. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and

Forecast, 2021 - 2031 (US\$ Million) - by Type

Table 20. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action

Table 21. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class

Table 22. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist

Table 23. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 24. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration

Table 25. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel

Table 26. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type

Table 27. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action

Table 28. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class

Table 29. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist

Table 30. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 31. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration

Table 32. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel

Table 33. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type

Table 34. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action

Table 35. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class

Table 36. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist

Table 37. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 38. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration

Table 39. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market  
- Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel

Table 40. Heat Map Analysis by Key Players

## List Of Figures

### LIST OF FIGURES

Figure 1. Middle East & Africa Anti-Obesity Drugs Market Segmentation - Country

Figure 2. PEST Analysis

Figure 3. Ecosystem: Anti-Obesity Drugs Market

Figure 4. Middle East & Africa Anti-Obesity Drugs Market - Key Market Dynamics

Figure 5. Impact Analysis of Drivers and Restraints

Figure 6. Middle East & Africa Anti-Obesity Drugs Market Revenue (US\$ Million), 2024 - 2031

Figure 7. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031

Figure 8. Prescription Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 9. OTC Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 10. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Mechanism of Action, 2024 and 2031

Figure 11. Centrally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 12. Peripherally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 13. Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 14. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031

Figure 15. GLP-1 Agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 16. Lipase Inhibitors: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 17. MC4R agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 18. Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 19. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031

Figure 20. Semaglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 21. Liraglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 22. Tirzepatide (Zepbound): Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 23. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031

Figure 24. Appetite Suppression: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 26. Metabolic Enhancement: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 27. Combination: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 28. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031

Figure 29. Oral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 30. Parenteral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 31. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031

Figure 32. Hospital Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 33. Online Channel: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 34. Retail Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 35. Middle East & Africa Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)

Figure 36. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 37. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 38. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 39. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 40. Company Positioning & Concentration

## I would like to order

Product name: Middle East & Africa Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)

Product link: <https://marketpublishers.com/r/M440CF5165EDEN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M440CF5165EDEN.html>